FDA Broadens Clearance for Agendia’s MammaPrint

Agendia, a world leader in molecular cancer diagnostics, announced Thursday that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages.
Forbes